Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...
Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously ...
On Thursday, Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, ...
Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes, may be a potential treatment for idiopathic intracranial hypertension (IIH). In a small phase 2 trial, ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. The finding contrasts with positive results from previous phase II studies ...
Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024 The NPM-115 clinical program will consist of a series of studies designed to support ...
Study over 24 weeks on patients with type 2 diabetes Says exenatide once-weekly shows superior glucose control Dec 15 (Reuters) - Amylin Pharmaceuticals Inc reported positive data from a study that ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results